CrushSCI.com
81.3Average days
82Median days
24Fastest days
131Longest days
6612025 publications

Paper Review Records

All Paper Review Records

23 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

85 days

Tri-modal PSMA PET/CT-MRI-US fusion biopsy for clinically significant prostate cancer: a prospective paired diagnostic study

Authors
Chen Huang; Lichen Jin; Yizhang Sun; Menglin Wu; Xuefeng Zhang; Xiaofeng Xu; Xuefeng He; Feng Qiu; Ximing Wang; Lingchuan Guo; Renpeng Huang; Jihui Li; Shengming Deng; Yuxin Lin; Xuedong Wei; Bin Zhang; Yuhua HuangShow moreShow less
Affiliations
1. Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, China; 2. School of Computer Science and Technology, Nanjing Tech University, Nanjing, China; 3. Carbon Medical Device Ltd, Shenzhen, China; 4. Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China; 5. Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, China; 6. Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, ChinaShow moreShow less
Source PDF DOI Publisher page
81 days

Correlation of 68 Ga-PSMA-11 PET/CT biodistribution with PSMA expression by immunohistochemistry in patients with HCC: A pilot prospective monocentric study

Authors
L. Vetrone; E. Prosperi; E. Prosperi; F. Vasuri; A. Degiovanni; V. Allegri; P. Castellucci; L. Zanoni; Cristina Nanni; M. Renzulli; V. Lucidi; A. Cattabriga; C. Malizia; M. Ravaioli; M. Cescon; S. Fanti; A. FarolfiShow moreShow less
Affiliations
1. Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 2. Department of Hepatobiliary Surgery and Liver Transplant, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 3. Pathology Unit, Santa Maria delle Croci Ravenna Hospital, Ravenna, Italy; 4. Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 5. Department of Medical and Surgical Sciences (DIMEC), Bologna University, Bologna, Italy; 6. Nuclear Medicine, AST Pesaro Urbino, Pesaro, Italy; 7. Department of Radiology, IRCSS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 8. Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ItalyShow moreShow less
Source PDF DOI Publisher page
50 days

Prognostic value and diagnostic performance of nectin-4-targeted [ 68 Ga]Ga-FZ-NR-1 PET/CT versus [ 18 F]FDG in recurrent or metastatic triple-negative breast cancer

Authors
Ye Li; Yuyun Sun; Li Sun; Dongliang Wang; Xiaoyu Pan; Xiaoping Xu; Shaoli SongShow moreShow less
Affiliations
1. Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, China; 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China; 3. Center for Biomedical Imaging, Fudan University, Shanghai, China; 4. Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, ChinaShow moreShow less
Source PDF DOI Publisher page
69 days

Practices and barriers in PET/CT use for critically ill patients: an international survey

Authors
Camilla Genovese; Jean-François Timsit; Michael ThyShow moreShow less
Affiliations
1. Department of Infectious Diseases, Ospedale Luigi Sacco, Milan, Italy; 2. Infectious Diseases Intensive Care Unit, Bichat-Claude Bernard University Hospital, AP-HP, Université Paris Cité, Paris, France; 3. Université Paris Cité and Université Sorbonne Paris Nord, INSERM, UMR1137, IAME, Paris, France; 4. UMR 1343, GEME, Pharmacologie et évaluation des thérapeutiques chez l’enfant et la femme enceinte, INSERM, Université Paris Cité, Paris, FranceShow moreShow less
Source PDF DOI Publisher page
82 days

Radium-223 decreases PD-L1 expression in bone metastases: A study with [ 89 Zr]Zr-atezolizumab PET and immunohistological correlation

Authors
Sui Wai Ling; Anouk de Jong; Mark Gorris; Marcel Segbers; Laura Graven; Marjolein van Driel; Geert van Leenders; Khrystany Isebia; Marjolijn Lub – de Hooge; Paul Hamberg; Niven Mehra; Mandy van Brakel; Ronald de Wit; Reno Debets; Elisabeth de Vries; Tessa Brabander; Jolanda de Vries; Astrid van der VeldtShow moreShow less
Affiliations
1. Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands; 2. Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; 3. Department of Medical BioSciences, Radboudumc, Nijmegen, the Netherlands; 4. Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; 5. Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; 6. Department of Clinical Pharmacy and Pharmacology, UMC Groningen, University of Groningen, Groningen, the Netherlands; 7. Department of Internal Medicine, Franciscus Gasthuis and Vlietland Hospital, Rotterdam, the Netherlands; 8. Department of Medical Oncology, Radboud UMC, Nijmegen, the Netherlands; 9. Department of Medical Oncology, UMC Groningen, University of Groningen, Groningen, the NetherlandsShow moreShow less
Source PDF DOI Publisher page
74 days

Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy

Authors
Emilio Francesco Giunta; Irene Marini; Ilaria Grassi; Silvia Nicolini; Flavia Foca; Monica Celli; Paola Caroli; Anna Sarnelli; Nicole Brighi; Giuseppe Schepisi; Manuela Monti; Ugo De Giorgi; Cristian Lolli; Maddalena SansoviniShow moreShow less
Affiliations
1. Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy; 2. Department of Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy; 3. Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy; 4. Department of Experimental Medicine, University of Salento, Lecce, ItalyShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.